Revenue YoY
-29.12%
Operating Income YoY
+8.50%
Net Income YoY
+4.90%
Net Margin Δ
-3666 bps
Net income bridge for Moderna (MRNA) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Net income: $163.00M+4.90%
Profit bridge breakdown for Moderna (MRNA) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Net Income | −$3.36B | — |
| Revenue | −$914.00M | -560.7% |
| Cost of Revenue | −$1.08B | -660.1% |
| Operating Expenses | $2.31B | +1415.3% |
| Other Income / Expense | −$49.00M | -30.1% |
| Income Tax | −$105.00M | -64.4% |
| Net Loss | −$3.19B | — |
- Prior Net Income−$3.36B
- Revenue−$914.00M
- Cost of Revenue−$1.08B
- Operating Expenses$2.31B
- Other Income / Expense−$49.00M
- Income Tax−$105.00M
- Net Loss−$3.19B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want the full P&L structure?Income Statement Waterfall
Frequently asked questions
Data & methodology
Moderna (MRNA) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement